ESTROPIPATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTROPIPATE (ESTROPIPATE).
Estropipate is a prodrug of estrone, converted to estradiol, which binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes involved in growth, differentiation, and function of female reproductive tissues.
| Metabolism | Estropipate is hydrolyzed by esterases in the liver and peripheral tissues to estrone, which is further metabolized via hydroxylation (CYP3A4, CYP1A2), conjugation (glucuronidation and sulfation), and interconversion to estradiol. |
| Excretion | Renal: 50-80% as conjugated and unconjugated estrogens (primarily estrone sulfate and estradiol glucuronide); biliary/fecal: 20-30% as glucuronide conjugates undergoing enterohepatic recirculation. |
| Half-life | Terminal elimination half-life of estradiol: ~12-14 hours (range 10-16 h); estrone: ~10-12 h; estrone sulfate: ~10-12 h. Clinical context: Steady-state achieved within 5-7 days; dosing interval typically once daily. |
| Protein binding | Estradiol: ~98% bound to sex hormone-binding globulin (SHBG) and albumin; estrone: ~80% bound to SHBG and albumin. |
| Volume of Distribution | Estradiol: Vd ~2.5 L/kg (range 1.5-3.0 L/kg), indicating extensive tissue distribution and binding to estrogen receptors. |
| Bioavailability | Oral: ~10-15% due to extensive first-pass metabolism in gut wall and liver; sublingual or buccal: ~20-25%; transdermal: ~90% (systemic delivery avoiding first-pass). |
| Onset of Action | Oral: 2-4 weeks for symptomatic relief of vasomotor symptoms; 6-12 months for maximal bone density effects. Transdermal or topical not applicable. |
| Duration of Action | Oral: 24 hours (once-daily dosing maintains therapeutic estradiol levels); clinical effect persists for 2-3 days after discontinuation due to enterohepatic recirculation. |
Oral: 1.25 mg to 2.5 mg daily for 3 weeks, followed by 1 week off; or continuous daily dosing of 0.625 mg to 1.25 mg.
| Dosage form | TABLET |
| Renal impairment | No specific adjustment recommended; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate (Child-Pugh A or B), reduce dose by 50% and monitor transaminases. |
| Pediatric use | Safety and efficacy not established; no standard dosing available. |
| Geriatric use | Use the lowest effective dose (0.625 mg orally daily) due to increased risk of thromboembolic events and endometrial cancer. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTROPIPATE (ESTROPIPATE).
| Breastfeeding | Estropipate is excreted in human milk; the M/P ratio is not specifically reported for estropipate. Estrogens can reduce milk production and alter composition. Breastfeeding is not recommended during therapy due to potential adverse effects on the infant (e.g., jaundice, vaginal bleeding) and impact on lactation. |
| Teratogenic Risk | Estropipate is a conjugated estrogen. First trimester: Increased risk of congenital anomalies (e.g., cardiovascular defects, neural tube defects) based on epidemiologic studies for estrogen use. Second/third trimester: Fetal harm may occur; estrogen exposure in utero has been associated with an increased risk of urogenital abnormalities in offspring and later-life reproductive tract cancers. After the first trimester, continued use is generally not recommended unless clearly indicated. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer in women with a uterus; risk of stroke and deep vein thrombosis; increased risk of breast cancer with combined estrogen-progestin therapy.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease (e.g., stroke, MI)","Known anaphylactic reaction or angioedema to estropipate","Known liver impairment or disease","Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders","Known or suspected pregnancy"]
| Precautions | ["Cardiovascular disorders: increased risk of stroke, DVT, pulmonary embolism","Malignancy: endometrial cancer (unopposed estrogen), breast cancer","Dementia: possible increased risk in women over 65","Gallbladder disease","Hypercalcemia in patients with breast cancer and bone metastases","Hereditary angioedema","Severe hypocalcemia in patients with hypoparathyroidism","Fluid retention","Exacerbation of endometriosis","Retinal vascular thrombosis"] |
Loading safety data…
| Fetal Monitoring | Monitor for fetal growth restriction, amniotic fluid abnormalities, and congenital anomalies via ultrasound if exposure occurs during first trimester. In later pregnancy, assess for gestational hypertension, thromboembolic events, and impaired glucose tolerance. Fetal heart rate monitoring may be considered if maternal complications arise. |
| Fertility Effects | Estropipate may inhibit ovulation by suppressing gonadotropin secretion, potentially impairing fertility during therapy. Effects on fertility are reversible upon discontinuation. In males, estrogen exposure can reduce spermatogenesis. |